Results for
"[search-keyword]"
Sponsor content
201 result(s) found, displaying 71 to 80
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Entrectinib
-
Prescription medicine decision summaryTGA decision: ENSPRYNG (satralizumab) is approved to treat adults with neuromyelitis optica spectrum disorders who have an AQP4-IgG.
-
Prescription medicine registrationActive ingredients: satralizumab.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Prescription medicine registrationActive ingredients: atezolizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Medicine administration kit, percutaneous, non-medicated, single-use.
-
Prescription medicine registrationActive ingredients: entrectinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HEMLIBRA emicizumab (rch) 105 mg/0.7 mL solution for injection vial.